PharmaEssentia Announces Health Canada Approval of BESREMi® (ropeginterferon alfa-2b) for Polycythemia Vera (PV) Jul 6, 2026 08:00AM
FDA approves BESREMi Pen for polycythemia vera treatment Jun 26, 2026 09:23AM
PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen™ (ropeginterferon alfa-2b-njft) for Polycythemia Vera Jun 26, 2026 09:23AM
PharmaEssentia acquires Canadian partner FORUS for $36.5 million Jun 11, 2026 08:00AM
PharmaEssentia Expands North American Commercial Footprint with Acquisition of Canadian Partner FORUS Therapeutics Jun 11, 2026 08:00AM
View Older Stories

Jun 10, 2026 10:13AM PharmaEssentia Announces Taiwan Approval of BESREMi® for Essential Thrombocythemia, Marking First Global Approval in ET
May 27, 2026 12:34PM PharmaEssentia Appoints Eric Vogel as U.S. Head of Commercialization Ahead of Potential Launch of BESREMi® in Essential Thrombocythemia
May 22, 2026 10:12AM PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026
Apr 27, 2026 10:24AM Taiwan's Representative to the United States Alexander Tah-ray Yui Visits PharmaEssentia's Puerto Rico Facility Alongside Puerto Rico Officials
Apr 2, 2026 10:09AM PharmaEssentia signs agreement for Puerto Rico manufacturing facility
Apr 2, 2026 10:09AM PharmaEssentia Signs Investment Agreement for New Manufacturing Facility in Puerto Rico
Mar 2, 2026 10:09AM PharmaEssentia Announces Japan Approval of High-Dose Dosing Regimen for BESREMi®
Feb 9, 2026 10:02AM PharmaEssentia Announces Plans to Establish New U.S. Manufacturing Facility in Puerto Rico to Support Global Growth of BESREMi®
Jan 27, 2026 09:00AM PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET)
Jan 13, 2026 08:00AM FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)
Jan 12, 2026 08:00AM PharmaEssentia Announces Positive Topline Phase 2b Data from EXCEED-ET Study Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
Dec 24, 2025 08:12AM PharmaEssentia USA Announces Appointment of Jeffrey Williams as Independent Director
Dec 15, 2025 08:00AM PharmaEssentia Announces Presentation at J.P. Morgan Healthcare Conference and Strategic Priorities for 2026
Nov 24, 2025 08:00AM PharmaEssentia trial results published in The Lancet Haematology
Nov 24, 2025 08:00AM PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in The Lancet Haematology
Nov 18, 2025 08:00AM PharmaEssentia Announces Presentations at ASH 2025
Nov 10, 2025 10:32AM PharmaEssentia USA Announces Appointment of Dr. Barry Flannelly as Independent Director
Jun 3, 2025 07:00AM PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms
May 20, 2025 07:00AM PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting
Mar 4, 2025 11:00AM PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage
Jan 6, 2025 10:00AM PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia
Jan 6, 2025 10:00AM CORRECTING and REPLACING PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia
Jan 2, 2025 10:03AM PharmaEssentia Reaffirms its Commitment to Robust and Reliable Access to Interferon Therapies Amid Global Supply Challenges
Nov 25, 2024 10:00AM PharmaEssentia Announces Nine Data Presentations at ASH Annual Meeting
Sep 4, 2024 09:00AM PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada
Jul 22, 2024 10:00AM PharmaEssentia Appoints Beth A. Krewson as Head of Legal
Jul 8, 2024 10:00AM PharmaEssentia Promotes Robert B. Geller, M.D. to General Manager
Jun 25, 2024 12:00PM PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera
Jun 20, 2024 01:00PM PharmaEssentia Appoints Fred Paster as Head of Commercial
May 29, 2024 02:30PM BESREMi® (Ropeginterferon alfa-2B) Shows Greatest Benefit Among Cytoreductive Therapies in Lowering Symptomatic Burden of Polycythemia Vera (PV): Real-World Analysis Published at ASCO
Apr 23, 2024 12:30PM PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of Legal
Apr 23, 2024 12:30PM CORRECTING and REPLACING PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical
Apr 1, 2024 08:00AM Analyses Find Patients With Polycythemia Vera (PV) Treated With BESREMi® (ropeginterferon alfa-2b) Had Increased Probability of Achieving Complete Hematologic Response
Feb 27, 2024 10:00AM PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) Now Recommended as a Preferred First-line Cytoreductive Therapy for Polycythemia Vera in Updated NCCN Clinical Practice Guidelines in Oncology
Feb 21, 2024 03:30PM Clinical Review of Pegylated Interferons Suggests Formulation and Mechanism of Action May Improve Outcomes for MPN Patients
Nov 2, 2023 09:58AM Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft
Aug 4, 2023 08:00AM New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera
May 23, 2023 08:00AM NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera
Apr 21, 2023 08:00AM PharmaEssentia Corporation Announces Closing of Global Depositary Receipt Offering, Generating US$462.7M to Support Growth Plans and Pipeline Development
Feb 23, 2023 08:00AM PharmaEssentia Initiates Phase 2b Trial of ropeginterferon alfa-2b-njft for Essential Thrombocythemia (ET) in North America
Feb 2, 2023 08:00AM Clinical Review of ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera
Dec 12, 2022 10:00AM New Ropeginterferon alfa-2b Data Show Importance of Proactive Care Earlier in the Polycythemia Vera Patient Journey
Nov 21, 2022 10:00AM Pharmaessentia to Host Investor Day in New York City on November 30, 2022
Nov 3, 2022 01:57PM Presentations on Ropeginterferon Alfa-2b During ASH Annual Meeting Highlight Momentum in the Care of Polycythemia Vera
Oct 20, 2022 08:00AM PharmaEssentia USA Expands Leadership With Executive Hires in Marketing, Medical Affairs and Communications and Advocacy
Aug 8, 2022 08:00AM Review of SURPASS-ET Trial Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia (ET) Published in Future Oncology
Jun 22, 2022 08:00AM PharmaEssentia Honored at the National Organization of Rare Disorders (NORD®) 2022 Rare Impact Awards for the Introduction of BESREMi® (ropeginterferon alfa-2b-njft) for Polycythemia Vera
May 16, 2022 07:00AM PharmaEssentia Announces Appointment of Meredith Manning to President of the Americas
Mar 2, 2022 08:00AM NCCN Clinical Practice Guidelines in Oncology Update Recommends BESREMi® (ropeginterferon alfa-2b-njft) for the Treatment of Polycythemia Vera
Feb 16, 2022 08:30AM PharmaEssentia Expands U.S. Leadership with Anjana Pursnani, Head of People and Jason Mitch, Head of Market Access
View Older Stories